Topiramate treatment of pediatric metabolic dysfunction–associated steatotic liver disease: A descriptive cohort study
Topiramate, as an adjunct to lifestyle intervention, may be considered in the treatment of pediatric MASLD, specifically in the context of failed lifestyle modification and inability to tolerate or qualify for other obesity pharmacotherapy.
Authors
- Ana Catalina Arce‐Clachar
- Jennifer A. Panganiban (ORCID: https://orcid.org/0009-0001-5220-668X)
- Marialena Mouzaki (ORCID: https://orcid.org/0000-0002-9809-6199)
- Pamela L. Valentino (ORCID: https://orcid.org/0000-0002-8227-2004)
- Andrea M. Tou (ORCID: https://orcid.org/0009-0000-2001-6825)
- Stavra A. Xanthakos (ORCID: https://orcid.org/0000-0001-9179-005X)
- Taisa Kohut (ORCID: https://orcid.org/0009-0008-9432-1425)
- Emily Carr
- Rima Fawaz (ORCID: https://orcid.org/0009-0005-2598-3319)
Institutions
- Cincinnati Children's Hospital Medical Center (US)
- Children's Hospital of Philadelphia (US)
- University of Miami (US)
- University of Washington (US)
- Yale University (US)
- University of Cincinnati Medical Center (US)
Publication Details
- Journal
- Journal of Parenteral and Enteral Nutrition
- Published
- 2024-12-25
- DOI
- https://doi.org/10.1002/jpen.2722
- Citations
- 5
- Primary Topic
- Diet and metabolism studies
- Type
- article
- Field-Weighted Citation Impact
- 1.63